CORT News

Pomerantz LLP Reminds Shareholders with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit – CORT

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Pomerantz LLP Reminds Shareholders with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit – CORT

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Robbins LLP Reminds CORT Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action

INVESTOR DEADLINE: Corcept Therapeutics (CORT) Investors with Substantial Losses Have Opportunity to Lead the Corcept Class Action Lawsuit– Hagens Berman

DEADLINE ALERT for PYPL, SMR, CORT, NAVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm

CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm

Pomerantz LLP Reminds Shareholders with Losses on their Investment in Corcept Therapeutics Incorporated – CORT